Deliverable: Transcripts

Objectives:

• Understand pulmonary arterial hypertension (PAH) market size
• Establish factors determining treatment initiation, initial treatment choice
Ascertain perception and use of endothelin receptor antagonists, PDE-5 inhbitors, and prostacyclins, including IV, oral and inhaled formulations
• Determine switching patterns and dosing trends

Products Highlighted:

• Tracleer® (bosentan tablets), Actelion Pharmaceuticals
• Revatio™ (sildenafil citrate), Pfizer
• Ambrisentan, Myogen
• Thelin® (sitaxsentan), Encysive Pharmaceuticals
• Flolan™ (epoprostenol sodium), Myogen
• Remodulin® (treprostinil sodium), United Therapeutics
• Ventavis® (iloprost), CoTherix
Topics:
• Treatment patterns for Class II and III treatment naïve patients
• Use of prostacyclins in all patients
• IV Remodulin dosing trends
• Switching among prostacyclins
• Opportunity for Ventavis and the inhaled prostacyclin class
• Inhaled Remodulin and TRIUMPH trial expectations
• Impact of oral therapies
• Endothelin receptor antagonists
• Emerging therapies

Quotes:

• “IV Remodulin patients start out with doses in the xx to xx ng/kg/min and increase from there optimal dose is likely xx-xx ng/kg/min depending on patient”
• “I think there is a role for inhaled therapy in patients who have…”
• “Approximately xx% of patients failing oral therapy are suitable for nebulized Ventavis therapy, if they are not suitable for IV therapy.”
• “I would offer to switch all my patients if…”
• “The driving force in the market is…”

Screening Criteria:

• Mix of US and EU panelists
• Pulmonologists treating PAH of all stages, using a variety of oral, IV, and inhaled therapies
• Aware of and or prescribing:
• IV Flolan
• IV Remodulin
• Tracleer
• Revatio
• Ambrisentan
• Sitaxsentan
• Ventavis

Representative Institutions:

• Hammersmith Hospital
• Harbor-UCLA Medical Center
• Henry Ford
• Hinsdale Hospital
• Hopital Louis Pradel
• SUNY - Stony Brook
• Temple University
• University of Miami
• University of Texas Health Science Center
• University of Virginia Health System